PL2249859T3 - Leczenie przerzutowego raka prostaty degareliksem - Google Patents

Leczenie przerzutowego raka prostaty degareliksem

Info

Publication number
PL2249859T3
PL2249859T3 PL09711390T PL09711390T PL2249859T3 PL 2249859 T3 PL2249859 T3 PL 2249859T3 PL 09711390 T PL09711390 T PL 09711390T PL 09711390 T PL09711390 T PL 09711390T PL 2249859 T3 PL2249859 T3 PL 2249859T3
Authority
PL
Poland
Prior art keywords
degarelix
treatment
prostate cancer
stage prostate
metastatic stage
Prior art date
Application number
PL09711390T
Other languages
English (en)
Inventor
Bo-Eric Persson
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2249859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL2249859T3 publication Critical patent/PL2249859T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PL09711390T 2008-02-11 2009-02-10 Leczenie przerzutowego raka prostaty degareliksem PL2249859T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
US14795609P 2009-01-28 2009-01-28
EP09711390.6A EP2249859B1 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix
PCT/IB2009/000370 WO2009101533A1 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix

Publications (1)

Publication Number Publication Date
PL2249859T3 true PL2249859T3 (pl) 2014-10-31

Family

ID=39718285

Family Applications (3)

Application Number Title Priority Date Filing Date
PL12165896T PL2505204T3 (pl) 2008-02-11 2009-02-10 Sposób leczenia raka prostaty za pomocą antagonisty GnRH degareliksu
PL09711390T PL2249859T3 (pl) 2008-02-11 2009-02-10 Leczenie przerzutowego raka prostaty degareliksem
PL13168404T PL2650012T3 (pl) 2008-02-11 2009-02-10 Leczenie przerzutowego stadium raka prostaty z zastosowaniem degareliksu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12165896T PL2505204T3 (pl) 2008-02-11 2009-02-10 Sposób leczenia raka prostaty za pomocą antagonisty GnRH degareliksu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13168404T PL2650012T3 (pl) 2008-02-11 2009-02-10 Leczenie przerzutowego stadium raka prostaty z zastosowaniem degareliksu

Country Status (25)

Country Link
US (16) US8841081B2 (pl)
EP (7) EP2650012B1 (pl)
JP (10) JP5876652B2 (pl)
KR (7) KR20100123714A (pl)
CN (4) CN107412726A (pl)
AU (2) AU2009213748B9 (pl)
BR (2) BRPI0908127A2 (pl)
CA (3) CA2714444A1 (pl)
CY (3) CY1115561T1 (pl)
DK (3) DK2249859T3 (pl)
EA (4) EA036695B1 (pl)
ES (3) ES2532709T3 (pl)
HK (4) HK1145011A1 (pl)
HR (3) HRP20140665T1 (pl)
IL (3) IL207295A (pl)
JO (1) JOP20090061B1 (pl)
MX (2) MX2010008817A (pl)
NZ (4) NZ587088A (pl)
PL (3) PL2505204T3 (pl)
PT (3) PT2650012E (pl)
RU (2) RU2504393C2 (pl)
SI (3) SI2650012T1 (pl)
TW (2) TWI442932B (pl)
WO (2) WO2009101530A1 (pl)
ZA (1) ZA201005697B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
CN102421414A (zh) 2009-05-01 2012-04-18 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US9260480B2 (en) 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
CN104853806A (zh) 2012-05-14 2015-08-19 理查德·G·佩斯泰尔 使用ccr5调节剂治疗癌症
EP2854831B1 (en) 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
CA2906894A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Compositions comprising elagolix for use in treating pain associated with endometriosis
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
EP3185881B1 (en) * 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
AU2016261770B2 (en) * 2015-05-12 2022-06-02 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
RU2019127027A (ru) * 2017-01-30 2021-03-01 Энтив Лимитед КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПО МЕНЬШЕЙ МЕРЕ ОДИН АНТАГОНИСТ GnRH
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CA3097340A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
WO2020028630A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
DE69330107T3 (de) 1992-02-12 2004-12-30 Daikyo Gomu Seiko, Ltd. Medizinisches Gerät
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5825730A (en) 1995-03-10 1998-10-20 Kabushiki Kaisha Toshiba Mastering machine having non-repetitive runout compensation
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
CA2336879C (en) 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
MXPA05003318A (es) 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
WO2009048932A2 (en) 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8105292B2 (en) * 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
EP2421887B1 (en) 2009-04-24 2015-04-22 Polypeptide Laboratories A/S Method for the manufacture of degarelix
CN102421414A (zh) * 2009-05-01 2012-04-18 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9260480B2 (en) * 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
EP2731607B1 (en) * 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
EP2854831B1 (en) 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix

Also Published As

Publication number Publication date
TW200938218A (en) 2009-09-16
CN101998861A (zh) 2011-03-30
HRP20150633T1 (hr) 2015-07-31
EA201300741A1 (ru) 2014-02-28
PL2650012T3 (pl) 2015-08-31
RU2010133481A (ru) 2012-03-20
NZ603932A (en) 2014-04-30
IL207295A (en) 2015-03-31
US9415085B2 (en) 2016-08-16
AU2009213748B2 (en) 2014-03-13
JP2016216455A (ja) 2016-12-22
JP2011511786A (ja) 2011-04-14
CY1116289T1 (el) 2017-02-08
EP4257197A2 (en) 2023-10-11
IL207400A0 (en) 2010-12-30
EP2505204A3 (en) 2013-01-09
HK1145011A1 (en) 2011-03-25
CN101939020B (zh) 2012-12-26
US20190167755A1 (en) 2019-06-06
PT2249859E (pt) 2014-07-31
US10729739B2 (en) 2020-08-04
MX2010008816A (es) 2010-09-07
EP3360565A1 (en) 2018-08-15
HRP20140665T1 (hr) 2014-10-10
US20130029910A1 (en) 2013-01-31
AU2009213748B9 (en) 2014-05-22
DK2249859T3 (da) 2014-06-02
EP2505204A2 (en) 2012-10-03
AU2009213751A1 (en) 2009-08-20
JP2016193910A (ja) 2016-11-17
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
US11766468B2 (en) 2023-09-26
JP5876652B2 (ja) 2016-03-02
RU2504393C2 (ru) 2014-01-20
US11826397B2 (en) 2023-11-28
PT2505204E (pt) 2015-03-26
CY1116341T1 (el) 2017-02-08
DK2650012T3 (da) 2015-06-15
DK2505204T3 (da) 2015-03-16
EA201300742A1 (ru) 2014-02-28
US9877999B2 (en) 2018-01-30
EP2249859B1 (en) 2014-04-23
AU2009213751B2 (en) 2014-09-25
AU2009213748A1 (en) 2009-08-20
US20170290879A1 (en) 2017-10-12
EA200901074A1 (ru) 2010-04-30
CA2714444A1 (en) 2009-08-20
JP5924866B2 (ja) 2016-05-25
SI2505204T1 (sl) 2015-04-30
JP6618967B2 (ja) 2019-12-11
MX2010008817A (es) 2010-09-09
SI2650012T1 (sl) 2015-06-30
US10973870B2 (en) 2021-04-13
US20140349935A1 (en) 2014-11-27
JP2014167009A (ja) 2014-09-11
KR20100123714A (ko) 2010-11-24
CN107412726A (zh) 2017-12-01
BRPI0908129A2 (pt) 2015-08-04
TW200938217A (en) 2009-09-16
BRPI0908127A2 (pt) 2015-08-04
JP2014141505A (ja) 2014-08-07
JP2011511785A (ja) 2011-04-14
HK1176552A1 (en) 2013-08-02
CN103990107A (zh) 2014-08-20
SI2249859T1 (sl) 2014-08-29
JP2022184898A (ja) 2022-12-13
CA2714445A1 (en) 2009-08-20
PL2505204T3 (pl) 2015-05-29
EA200901075A1 (ru) 2010-04-30
ES2532709T3 (es) 2015-03-31
JP2022133426A (ja) 2022-09-13
US20090203623A1 (en) 2009-08-13
RU2010133480A (ru) 2012-03-20
US20200237854A1 (en) 2020-07-30
EP4257197A3 (en) 2023-11-29
KR20180118830A (ko) 2018-10-31
CA3235099A1 (en) 2009-08-20
US20170035833A1 (en) 2017-02-09
US20220218782A1 (en) 2022-07-14
EP2799085A1 (en) 2014-11-05
EP2249859A1 (en) 2010-11-17
ES2540235T3 (es) 2015-07-09
KR101542480B1 (ko) 2015-08-07
HK1190912A1 (en) 2014-07-18
EA026521B1 (ru) 2017-04-28
EA017582B1 (ru) 2013-01-30
US9579359B2 (en) 2017-02-28
KR20100126362A (ko) 2010-12-01
US20220226422A1 (en) 2022-07-21
EP2249858A1 (en) 2010-11-17
HRP20150290T1 (hr) 2015-04-10
EP2650012B1 (en) 2015-03-25
EP2505204B1 (en) 2014-12-24
JP6254042B2 (ja) 2017-12-27
CN101939020A (zh) 2011-01-05
KR20140130757A (ko) 2014-11-11
US20220323538A1 (en) 2022-10-13
KR20150091543A (ko) 2015-08-11
EP2650012A1 (en) 2013-10-16
US20140113870A1 (en) 2014-04-24
TWI442932B (zh) 2014-07-01
US20220218783A1 (en) 2022-07-14
KR20230088848A (ko) 2023-06-20
WO2009101530A1 (en) 2009-08-20
TWI539959B (zh) 2016-07-01
CA2714445C (en) 2018-01-16
JP2018039814A (ja) 2018-03-15
US20090203622A1 (en) 2009-08-13
US20240316142A1 (en) 2024-09-26
US10695398B2 (en) 2020-06-30
IL207295A0 (en) 2010-12-30
RU2504394C2 (ru) 2014-01-20
IL223124A0 (en) 2012-12-31
HK1198243A1 (en) 2015-03-20
JOP20090061B1 (ar) 2021-08-17
US20220031801A1 (en) 2022-02-03
JP2024028869A (ja) 2024-03-05
KR20220009504A (ko) 2022-01-24
IL207400A (en) 2014-12-31
NZ603958A (en) 2013-03-28
JP6189234B2 (ja) 2017-08-30
WO2009101533A1 (en) 2009-08-20
EA020543B1 (ru) 2014-12-30
US8841081B2 (en) 2014-09-23
PT2650012E (pt) 2015-06-30
ZA201005697B (en) 2014-01-24
US20210128673A1 (en) 2021-05-06
CY1115561T1 (el) 2017-01-04
EA036695B1 (ru) 2020-12-09
NZ587088A (en) 2012-12-21
ES2479441T3 (es) 2014-07-24

Similar Documents

Publication Publication Date Title
HK1190912A1 (en) Treatment of metastatic stage prostate cancer with degarelix
ZA201008140B (en) Treatment of metastatic tumors
EP2461814A4 (en) PROSTATE CANCER TREATMENT
IL215108A0 (en) Amatoxin-armed target-binding moieties for the treatment of cancer
HK1175476A1 (en) Cancer treatment
IL218575A0 (en) Treatment of cancer
IL217291A0 (en) Exosome based treatment of cancer
EP2310006A4 (en) TREATMENT OF CANCER
EP2197533A4 (en) ABLATION OF PROSTATE CANCER
ZA201107879B (en) Composition for the treatment of prostate cancer
GB0804496D0 (en) Treating cancer
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
GB0916686D0 (en) Treatment of cancer
HK1258957A1 (zh) 用地加瑞克治療轉移階段前列腺癌
GB0809046D0 (en) Cancer treatment
GB0822016D0 (en) Treatment of metastatic cancer
GB0705205D0 (en) Treatment of metastatic cancer
AU2008906236A0 (en) Prostate Cancer Treatment Rectal Probe
GB0822018D0 (en) Prevention of metastatic cancer
GB0612369D0 (en) Treatment of metastatic cancer
GB0712513D0 (en) Treatment of cancer
GB0921757D0 (en) Treatment of cancer
GB0809730D0 (en) Improvements in the chemotherapy of cancer
GB0818566D0 (en) Improvements in the chemotherapy of cancer
GB0813361D0 (en) Treatment of cancer fatigue